Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean (TXA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03364491 |
Recruitment Status :
Completed
First Posted : December 6, 2017
Last Update Posted : February 2, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obstetrical Complications Hemorrhage Labor and Delivery | Drug: Tranexamic Acid Drug: Placebo | Phase 3 |
Obstetrical hemorrhage is a common cause of maternal morbidity and mortality worldwide. The frequency and severity of hemorrhage is significantly higher after cesarean delivery than vaginal delivery. Recent evidence has emerged about the importance of the fibrinolytic pathway in the pathophysiology of hemorrhage in different clinical scenarios including trauma-associated bleeding, cardiovascular surgery, and obstetrical hemorrhage. Tranexamic acid (TXA) inhibits fibrinolysis and is used routinely to prevent hemorrhage in trauma cases and high risk surgeries. Randomized trials of TXA as a prophylaxis to prevent hemorrhage in cesarean delivery have been small and of mixed quality; however meta-analysis suggests that it is effective.
This study is a randomized placebo-controlled trial of 11,000 women to assess whether tranexamic acid as prophylaxis lowers the risk of postpartum hemorrhage in women undergoing a cesarean delivery.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 11000 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Participants will be randomized to receive either TXA (1 gram [10cc] mixed with 40 cc of normal saline) administered intravenously or a placebo control of 50 cc of normal saline administered intravenously |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | The patient nor the clinical staff will be aware of the treatment assignment. The TXA or placebo solutions will be prepared by the center research pharmacies. |
Primary Purpose: | Prevention |
Official Title: | Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial |
Actual Study Start Date : | March 12, 2018 |
Actual Primary Completion Date : | August 31, 2021 |
Actual Study Completion Date : | September 30, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Tranexamic Acid
Tranexamic Acid for intravenous administration
|
Drug: Tranexamic Acid
A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
Other Name: TXA |
Placebo Comparator: Placebo
Normal saline for intravenous administration
|
Drug: Placebo
50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward) |
- Maternal death or transfusion of packed red blood cells [ Time Frame: by hospital discharge or by 7 days postpartum, whichever is sooner ]Maternal death or transfusion of 1 or more units of packed red blood cells.
- Estimated blood loss [ Time Frame: From skin incision to transfer from operating room, average of 1 hour ]Estimated blood loss in milliliters, collected from anesthesia record and operative report
- Maternal death or transfusion of packed red blood cells [ Time Frame: within 7 days postpartum ]Maternal death or transfusion of 1 or more units of packed red blood cells.
- Composite of surgical or radiological interventions to control bleeding and related complications, or maternal death [ Time Frame: within 7 days postpartum ]Interventions such as: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology
- Composite of maternal death, thromboembolic events (venous or arterial), ischemic stroke, myocardial infarction, new-onset seizure activity, or admission to the intensive care unit for more than 24 hours [ Time Frame: within 6 weeks postpartum ]
- Transfusion related acute lung injury (TRALI) [ Time Frame: within 7 days postpartum ]Ratio of partial pressure of oxygen to inspired fraction of oxygen below 300 within 6 hours of receiving a blood product with bilateral pulmonary edema on chest x-ray
- Transfusion of other blood products [ Time Frame: within 7 days postpartum ]Transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates
- Transfusion of 4 or more units of packed red blood cells [ Time Frame: within 7 days postpartum ]Amount of packed red blood cells transfused, categorized as 0 to 3 units, or 4 or more units
- Acute kidney injury [ Time Frame: within 7 days postpartum ]Acute elevation of serum creatinine of ≥ 0.3 mg/dL during a period of 48 hours
- Thromboembolic events (venous or arterial), ischemic stroke, or myocardial infarction [ Time Frame: within 6 weeks postpartum ]
- New-onset seizure activity [ Time Frame: within 6 weeks postpartum ]Maternal seizure activity, confirmed by central review, whose onset is after randomization
- Postpartum infectious complications [ Time Frame: within 6 weeks postpartum ]Infectious complications such as: endometritis, surgical site infection, pelvic abscess
- Admission to the intensive care unit for more than 24 hours [ Time Frame: within 6 weeks postpartum ]Any admission to the intensive care unit that lasts more than 24 hours
- Maternal death [ Time Frame: within 6 weeks postpartum ]
- Use of uterotonics other than oxytocin [ Time Frame: within 48 hours postpartum ]Any use of uterotonics such as prostaglandins or methergine, but excluding oxytocin
- Surgical or radiologic interventions to control bleeding and related complications [ Time Frame: within 7 days postpartum ]Interventions such as: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology
- Change in hemoglobin [ Time Frame: from 4 weeks before delivery to 48 hours postpartum ]Change in hemoglobin from before cesarean to lowest post-operative measured
- TXA side effects [ Time Frame: within 24 hours postpartum ]Maternal TXA-related side-effects (nausea, vomiting, dizziness)
- Open label use of TXA or other antifibrinolytic [ Time Frame: within 7 days postpartum ]Use of any amount of open-label TXA (not blinded study drug) or other antifibrinolytic (eg., Amicar)
- Length of stay [ Time Frame: Until hospital discharge, an average of 3 days ]Mother's length of stay from delivery to discharge
- Hospital re-admission [ Time Frame: within 6 weeks postpartum ]Re-admission to the hospital after initial postpartum discharge
- Any transfusion-associated reactions [ Time Frame: within 7 days postpartum ]One more transfusion-associated reactions, such as fever, urticaria, anaphylaxis, alloimmunization
- Composite of treatments and interventions in response to bleeding and related complications [ Time Frame: within 7 days postpartum ]Treatments and interventions such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Scheduled or unscheduled cesarean delivery
- Singleton or twin gestation
Exclusion Criteria:
- Age less than 18 years
- Transfusion or planned transfusion of any blood products during the current admission because the primary outcome is already pre-determined and the need for transfusion will be unrelated to perioperative hemorrhage
- Recent diagnosis or history of venous thromboembolism or arterial thrombosis because TXA is a risk factor for thromboembolism, and its use is contraindicated
- Known congenital or acquired thrombophilias, including antiphospholipid antibody syndrome, because of the increased risk of thrombosis
- Seizure disorder (including eclampsia) because TXA is a GABA receptor antagonist, and its use has been associated with postoperative seizures
- Serum creatinine 1.2 or higher or on dialysis, with renal disease, or a history of renal insufficiency, because TXA is substantially excreted by the kidney, and impaired renal function may increase the risk of toxic reactions.
- Sickle cell disease, because of substantial use of perioperative transfusion unrelated to hemorrhage. Sickle cell trait is not an exclusion per se.
- Autoimmune diseases such as lupus, rheumatoid arthritis, Sjogren's disease, and inflammatory bowel disease because of hypercoagulability and the increased risk of thrombosis or thromboembolism
- Need for therapeutic dose of anticoagulation before delivery, because the risk of thrombosis may be increased with TXA
- Treatment with clotting factor concentrates, because the risk of thrombosis may be increased with TXA
- Presence of frank hematuria, because the risk of ureteral obstruction in those with upper urinary tract bleeding may be increased with TXA
- Patient refusal of blood products because the primary outcome is then pre-determined
- Receipt of TXA; or planned or expected use of TXA prophylaxis
- Active cancer, because of risk of thromboembolism
- Congestive heart failure requiring treatment, because of risk of thrombosis
- History of retinal disease, because the risk of central retinal artery or vein obstruction may be increased with TXA
- Acquired defective color vision or subarachnoid hemorrhage, since TXA is contraindicated
- Hypersensitivity to TXA or any of the ingredients
- No hemoglobin result available from the last 4 weeks, since it is necessary to measure the post-operative change in hemoglobin
- Scheduled cesarean delivery and quota for scheduled deliveries already met. Quotas on the number of scheduled and unscheduled deliveries will be placed to ensure approximately equal distribution of scheduled and unscheduled cesarean deliveries.
- Participation in this trial in a previous pregnancy. Patients who were screened in a previous pregnancy, but not randomized, may be included.
- Participating in another intervention study where the primary outcome includes postpartum bleeding or thromboembolism, or the study intervention directly affects postpartum bleeding or thromboembolism
- Receipt of uterotonics, other than oxytocin, or planned or expected use of uterotonic prophylaxis
- Symptomatic for COVID-19 infection within 14 days prior to delivery

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03364491
United States, Alabama | |
University of Alabama - Birmingham | |
Birmingham, Alabama, United States, 35233 | |
United States, Illinois | |
Northwestern University-Prentice Hospital | |
Chicago, Illinois, United States, 60611 | |
United States, New York | |
Columbia University | |
New York, New York, United States, 10032 | |
United States, North Carolina | |
University of North Carolina - Chapel Hill | |
Chapel Hill, North Carolina, United States, 27599 | |
United States, Ohio | |
Case Western Reserve-MetroHealth | |
Cleveland, Ohio, United States, 44109 | |
Ohio State University Hospital | |
Columbus, Ohio, United States, 43210 | |
United States, Pennsylvania | |
Hospital of the University of Pennsylvania | |
Philadelphia, Pennsylvania, United States, 19104 | |
Magee Women's Hospital of UPMC | |
Pittsburgh, Pennsylvania, United States, 15213 | |
United States, Rhode Island | |
Brown University | |
Providence, Rhode Island, United States, 02905 | |
United States, Texas | |
University of Texas Medical Branch | |
Galveston, Texas, United States, 77555 | |
University of Texas - Houston | |
Houston, Texas, United States, 77030 | |
United States, Utah | |
University of Utah Medical Center | |
Salt Lake City, Utah, United States, 84132 |
Principal Investigator: | Rebecca Clifton, Ph.D. | The George Washington University Biostatistics Center | |
Study Director: | Andrew Bremer, MD, PhD, MAS | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | |
Study Chair: | Louis Pacheco, MD | UTMB |
Responsible Party: | The George Washington University Biostatistics Center |
ClinicalTrials.gov Identifier: | NCT03364491 |
Other Study ID Numbers: |
HD36801-TXA U10HD036801 ( U.S. NIH Grant/Contract ) UG1HD087230 ( U.S. NIH Grant/Contract ) UG1HD027869 ( U.S. NIH Grant/Contract ) UG1HD040500 ( U.S. NIH Grant/Contract ) UG1HD034208 ( U.S. NIH Grant/Contract ) UG1HD027915 ( U.S. NIH Grant/Contract ) UG1HD040485 ( U.S. NIH Grant/Contract ) UG1HD053097 ( U.S. NIH Grant/Contract ) UG1HD040544 ( U.S. NIH Grant/Contract ) UG1HD040545 ( U.S. NIH Grant/Contract ) UG1HD040560 ( U.S. NIH Grant/Contract ) UG1HD040512 ( U.S. NIH Grant/Contract ) UG1HD087192 ( U.S. NIH Grant/Contract ) |
First Posted: | December 6, 2017 Key Record Dates |
Last Update Posted: | February 2, 2022 |
Last Verified: | January 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | The dataset will be shared per NIH policy after the completion and publication of the main analyses. Requests for datasets can be sent to mfmudatasets@bsc.gwu.edu. |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Tranexamic Acid Hemorrhage Cesarean |
Hemorrhage Pathologic Processes Tranexamic Acid Antifibrinolytic Agents |
Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Hemostatics Coagulants |